Stock Ratings / Health Care / NEPH / financials

CVRX (31) DRIO (34) XTNT (65) TELA (39) ⌘ Pro Terminal →

Nephros Inc. (NEPH) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.17 -3.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.15

Nephros Inc. (NEPH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $35.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.17 (-3.06% 1D, market cap $35.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NEPH ranks #191 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEPH compare to CVRX and DRIO in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and DRIO (DarioHealth Corp.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEPH?

▼

Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (62% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.15 (-0.74%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 8.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY NEPH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 8.5% FCF Margin ($1.6M FCF) & 61.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$3.57+3.1% Next Q

Q2 (-2Q)

Grade C+$3.68-1.4% Next Q

Q3 (-1Q)

Grade C+$3.63-12.7% Next Q

Current

Grade C-$3.17+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NEPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, NEPH faces multiple-compression risk if 29.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.89) or 200D SMA ($3.66) invalidates the momentum regime and cuts Target Base ($3.18) toward Bear Floor ($2.48).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NEPH Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$1.6M (8.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $14.2M

FY24

Rev $14.2M

FY25

Rev $18.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$18.8M	61.9%	6.1%	$1.2M	$1.6M	18.9%
FY 2024	$14.2M	61.6%	0%	$74.0K	-$547.0K	0.1%
FY 2023	$14.2M	61.9%	-11.2%	-$1.6M	$827.0K	18.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEPH)

✓Walkthrough of NEPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.26%🛡️ HOLDING TREND SUPPORT

2026-11-02O $3.17H $3.27L $3.17C $3.17VOL 72.4K

RES: $5.68SUP: $2.99SMA50: $3.89SMA200: $3.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEPH Butterfly Map → + Track NEPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.0%/yr Implied 5Y Growth

vs. +32.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEPH)

Health Care Rank #191 of 1016 ⚔️ CVRX vs NEPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEPH vs. CVRX, DRIO, XTNT, TELA)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nephros Inc. (NEPH) ranks #191 by composite RQD confidence (59/100, grade C-) and #789 by equity capitalization ($35.5M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NEPH at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEPH ACTIVE Nephros Inc.	C-	59/100	29.8x	61.9%	18.9%	-3.06%	$35.5M	Benchmark Subject
CVRX CVRx Inc.	E	31/100	—	85.3%	-35.0%	-1.05%	$38.0M	/cvrx-vs-neph →
DRIO DarioHealth Corp.	E	34/100	—	56.6%	-35.0%	-9.37%	$32.4M	/drio-vs-neph →
XTNT Xtant Medical Holdings Inc.	C	65/100	—	62.9%	12.8%	-3.51%	$40.7M	/xtnt-vs-neph →
TELA TELA Bio Inc.	D-	39/100	—	67.7%	-35.0%	-11.95%	$41.5M	/tela-vs-neph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001196298

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nephros Inc. (NEPH) reported GAAP revenue of $18.8M (+32.7% vs. FY2024 revenue of $14.2M , and +32.0% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $1.6M, and free cash flow of $1.6M (+392.5% YoY). On the balance sheet, NEPH closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$18.8M	$1.2M	$1.6M	$1.6M	$13.6M	—
FY2024 (FY)	2024-12-31	$14.2M	$74.0K	-$492.0K	-$547.0K	$11.2M	—
FY2023 (FY)	2023-12-31	$14.2M	-$1.6M	$827.0K	$827.0K	—	—

3. NEPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NEPH compare to CVRX and DRIO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NEPH?

Where is NEPH trading relative to its 50-day, 200-day, and 52-week technical levels?

NEPH last traded at $3.17 (-3.06% on volume of 12,421 shares), positioning the stock -18.51% below its 50-day simple moving average ($3.89) and -13.39% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.66 to $6.42, NEPH sits at the 13.6% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.77 to $3.57).

NEPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Nephros Inc. (NEPH)?

In FY 2025 (10-K), NEPH converted $18.8M of revenue into a 61.9% gross margin, 6.1% operating margin, and $1.6M in free cash flow (8.5% FCF margin).

Direct Sub-Reports: NEPH RQD Cockpit NEPH 12M Forecast NEPH Earnings & Move NEPH Dividends & DRIP NEPH Insiders & 13F NEPH Whale Options NEPH Profit Sankey NEPH News & Why

Sector Peer Dials

Xtant Medical Holdings Inc.

NEPH Core Snapshot

Market Cap $35.5M

Trailing / Fwd P/E 29.8x / 25.0x

Gross Profit Margin 61.9%

Return on Capital (ROIC) 18.9%

Free Cash Flow Yield 4.50%

12M Base Price Target $3.18

FREE TRADER TOOLS

Own NEPH Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With NEPH → 🏆 Trade NEPH in $100K Prop Arena →

NEPH Wire

Why It Moved →

Direct Company Event TradingView • 14h ago

Nephros, Inc. Estimates – NASDAQ:NEPH

Direct Company Event Yahoo! Finance Canada • 17h ago

Nephros, Inc. (NEPH) Seasonal Returns Chart - Yahoo Finance

Direct Company Event https://www.siam.in/ • 20h ago

Nephros Inc. (NEPH) Edges Lower to $3.52 as Shares Sit Midway Between Key Support and Resistance - Late Stage Breakouts

Peer / Ecosystem Wire Stock Titan • 23h ago

Davion Healthcare Plc (DAVI) Stock Price, News & Analysis

Direct Company Event Yahoo Finance • 1d ago

Nephron Pharmaceuticals’ CEO is out. Here’s past coverage of the company.

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NEPH — Nephros Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:48:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NEPH scores 59 out of 100, equating to a C- grade and a "Roarable Hold — Cautious Neutral" verdict. The five pillars are:

Fundamental Cash Engine: 16 / 20. Per the Roarable RQD rating, this reflects ROIC of 18.9% and an FCF yield of 4.5%. This is the strongest pillar and suggests the business currently converts capital into returns at a respectable rate relative to its market value.
Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, institutional accumulation and options positioning score very low. For a prospective investor, this implies limited evidence of large institutional conviction behind the stock.
Insider Conviction: 15 / 20. Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scores moderately well. The pillar is supported by the rating but the underlying insider transactions are not itemized in the source data.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta of 1.0 and sector sensitivity produce a middling score, indicating the stock tracks broad market movement without a clear macro tailwind.
Forensic Balance Sheet: 15 / 20. Per the Roarable RQD rating, Altman Z of 2.5, Piotroski F of 8/9, and Debt/Equity of 0.5 support a reasonably sound balance sheet.

Investment implications: the rating's strengths are cash generation and balance sheet quality; its weaknesses are institutional demand and macro fit. Valuation is the central tradeoff. Per the Market Data section, P/E (TTM) is 29.8 and EV/EBITDA is 26.3, which are elevated multiples for a company with a 6.1% operating margin. A prospective investor would need to weigh the 18.9% ROIC against these multiples and the thin institutional support. This is an educational summary of the rating, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
3.27	$35.5M	29.8	25	26.3	0.11	0%	1.0	$2.66 - $6.42	18.9%

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$18.8M	$1.1M	$1.2M	N/A	$1.6M	$5.4M	N/A
FY 2024	$14.2M	$0.0M	$0.1M	N/A	$-0.5M	$3.8M	N/A
FY 2023	$14.2M	$-1.6M	$-1.6M	N/A	$0.8M	N/A	N/A

Per the SEC financials, revenue rose from $14.2M in FY 2024 to $18.8M in FY 2025, and net income moved from $0.1M to $1.2M. Per the market data, operating margin is 6.1% and net margin is 6.4%, with ROIC at 18.9%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 8/9, with Debt/Equity of 0.5. Debt figures are not reported in the financials table.

Open Questions

What is the debt balance and maturity profile, given that debt is reported as N/A across all periods?
What drove the swing from a $1.6M operating loss in FY 2023 to $1.1M operating income in FY 2025?
Who are the institutional and insider holders, and what is their recent transaction activity?
Does the FY 2024 revenue figure ($14.2M) correctly match the FY 2023 figure, or does it reflect a reporting issue?
Which company is the subject of the Nephron Pharmaceuticals CEO news, and is it related to NEPH?

NEPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nephros Inc. (NEPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEPH Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 14h ago

Nephros, Inc. Estimates – NASDAQ:NEPH

TradingView report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 17h ago

Nephros, Inc. (NEPH) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 20h ago

Nephros Inc. (NEPH) Edges Lower to $3.52 as Shares Sit Midway Between Key Support and Resistance - Late Stage Breakouts

https://www.siam.in/ report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

Davion Healthcare Plc (DAVI) Stock Price, News & Analysis

Stock Titan report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Nephron Pharmaceuticals’ CEO is out. Here’s past coverage of the company.

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Lou Kennedy is no longer Nephron Pharmaceuticals CEO

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Nephron's Lou Kennedy out as CEO in 'leadership transition’. What we know.

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Nephros, Inc. (NEPH) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEPH Bull vs. Bear Conversation Board — What's Your Call at $3.17?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEPH 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.53 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NEPH (C- • RQD 59/100) a Buy at $3.27?

Welcome to the NEPH (Nephros Inc.) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Medical/Dental Instruments. Bulls point to capital efficiency (18.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.62 (-19.9%)

Spot @ $3.27

Pump the brakes on NEPH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NEPH, but look at what you are paying: 29.8x trailing P/E with 61.9% gross margins. Unless Nephros Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.19 (+28.1%)

Spot @ $3.27

NEPH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NEPH, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $3.27 (52-wk range $2.66 - $6.42), any beat on forward guidance forces shorts and underweight funds to chase.